144 related articles for article (PubMed ID: 8029802)
1. Prevention of intra-coronary thrombosis in the anaesthetised dog: the importance of thromboxane A2 and thrombin.
White BP; Sullivan AT; Lumley P
Thromb Haemost; 1994 Mar; 71(3):366-74. PubMed ID: 8029802
[TBL] [Abstract][Full Text] [Related]
2. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
Rote WE; Mu DX; Bates ER; Nedelman MA; Lucchesi BR
J Cardiovasc Pharmacol; 1994 Feb; 23(2):203-11. PubMed ID: 7511748
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the inhibitory effects of the TXA2 receptor antagonist, vapiprost, and other antiplatelet drugs on arterial thrombosis in rats: possible role of TXA2.
Takiguchi Y; Wada K; Nakashima M
Thromb Haemost; 1992 Oct; 68(4):460-3. PubMed ID: 1448780
[TBL] [Abstract][Full Text] [Related]
4. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
[TBL] [Abstract][Full Text] [Related]
5. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
Chen LY; Nichols WW; Mattsson C; Teger-Nilson AC; Wallin R; Saldeen TG; Mehta JL
Cardiovasc Res; 1995 Dec; 30(6):866-74. PubMed ID: 8746200
[TBL] [Abstract][Full Text] [Related]
6. Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog.
Shebuski RJ; Smith JM; Storer BL; Granett JR; Bugelski PJ
J Pharmacol Exp Ther; 1988 Aug; 246(2):790-6. PubMed ID: 3136245
[TBL] [Abstract][Full Text] [Related]
7. Roles of platelet-activating factor, thromboxane A2, ADP and thrombin in thrombogenesis in the guinea pig.
Hirata Y; Takiguchi Y; Wada K; Matsuno H; Umemura K; Uematsu T; Nakashima M
Eur J Pharmacol; 1993 Feb; 231(3):421-5. PubMed ID: 8449234
[TBL] [Abstract][Full Text] [Related]
8. Inhibition by combined therapy with ticlopidine and aspirin of enhanced platelet aggregation during physical exercise in patients with coronary artery disease.
Kitai T; Nishikawa M; Tanigawa T; Okinaka T; Wada H; Shiku H; Ikeda Y; Ito M; Isaka N; Nakano T
Am Heart J; 2001 Aug; 142(2):E1. PubMed ID: 11479480
[TBL] [Abstract][Full Text] [Related]
9. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis.
Lewis GD; Witzke C; Colon-Hernandez P; Guerrero JL; Bloch KD; Semigran MJ
J Am Coll Cardiol; 2006 Apr; 47(7):1471-7. PubMed ID: 16580539
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effect of clopidogrel, vapiprost and argatroban on the middle cerebral artery thrombosis in the rat.
Umemura K; Kawai H; Ishihara H; Nakashima M
Jpn J Pharmacol; 1995 Mar; 67(3):253-8. PubMed ID: 7630043
[TBL] [Abstract][Full Text] [Related]
11. DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs.
Guth BD; Müller TH
Basic Res Cardiol; 1997 Jun; 92(3):181-90. PubMed ID: 9226103
[TBL] [Abstract][Full Text] [Related]
12. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
[TBL] [Abstract][Full Text] [Related]
13. Thrombostatin inhibits cyclic flow variations in stenosed canine coronary arteries.
Hasa AA; Schmaier AH; Warnock M; Normolle D; Driscoll E; Lucchesi BR; Werns SW
Thromb Haemost; 2001 Nov; 86(5):1296-304. PubMed ID: 11816721
[TBL] [Abstract][Full Text] [Related]
14. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin.
Meyer BJ; Badimon JJ; Chesebro JH; Fallon JT; Fuster V; Badimon L
Circulation; 1998 Feb; 97(7):681-5. PubMed ID: 9495304
[TBL] [Abstract][Full Text] [Related]
15. Reduction of in vivo coronary artery thrombosis by the novel thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid.
Fiedler VB; Perzborn E; Seuter F; Rosentreter U; Böshagen H
Arzneimittelforschung; 1989 Dec; 39(12):1527-30. PubMed ID: 2624600
[TBL] [Abstract][Full Text] [Related]
16. Comparative antiplatelet effects of aspirin, vapiprost and GR144053, a GPIIb/IIIa antagonist, with a special reference to the role of platelet microaggregates.
Matsuno H; Kozawa O; Nagashima S; Kanamaru M; Uematsu T
Br J Pharmacol; 1999 Jul; 127(5):1129-34. PubMed ID: 10455258
[TBL] [Abstract][Full Text] [Related]
17. Maximal blockade of TxA2 without compromised PGI2 formation; a superior profile of the TxA2 receptor blocking drug GR32191 over aspirin.
Lumley P; Keery RJ; Wharton KA; White BP; Watts IS
Adv Prostaglandin Thromboxane Leukot Res; 1991; 21B():603-6. PubMed ID: 1825385
[No Abstract] [Full Text] [Related]
18. [Resistance to desaggregants: causes, clinical implication, methods of diagnosis and correction].
Kremneva LV; Shalaev SV
Ter Arkh; 2008; 80(12):89-95. PubMed ID: 19227916
[No Abstract] [Full Text] [Related]
19. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit.
Herbert JM; Dol F; Bernat A; Falotico R; Lalé A; Savi P
Thromb Haemost; 1998 Sep; 80(3):512-8. PubMed ID: 9759636
[TBL] [Abstract][Full Text] [Related]
20. Potent low dose platelet inhibitory effects of clopidogrel and aspirin on coronary thrombus formation in an animal model of acute unstable angina.
Bierbach B; Horstick G; Berg O; Heimann A; Münzel T; Vahl CF; Kempski O; Darius H
Thromb Haemost; 2006 Feb; 95(2):354-61. PubMed ID: 16502561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
